Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jay N Cohn

Showing results (131-140 of 171) with videos related to

Pageof 18
Sort By:
Journal of Cardiac Failure|August 4, 2012
Effect of fixed-dose combined isosorbide dinitrate/hydralazine in elderly patients in the African-American heart failure trialAnne L Taylor, Michael L Sabolinski, S William Tam, et al.
Clinical Chemistry|June 17, 2006
Direct comparison of B-type natriuretic peptide (BNP) and amino-terminal proBNP in a large population of patients with chronic and symptomatic heart failure: the Valsartan Heart Failure (Val-HeFT) dataSerge Masson, Roberto Latini, Inder S Anand, et al.
JACC. Heart Failure|October 13, 2014
G-protein beta-3 subunit genotype predicts enhanced benefit of fixed-dose isosorbide dinitrate and hydralazine: results of A-HeFTDennis M McNamara, Anne L Taylor, S William Tam, et al.
Journal of Cardiac Failure|December 11, 2007
Clinical, neurohormonal, and inflammatory markers and overall prognostic role of chronic obstructive pulmonary disease in patients with heart failure: data from the Val-HeFT heart failure trialLidia Staszewsky, Maylene Wong, Serge Masson, et al.
Journal of Cardiac Failure|July 26, 2002
African-American Heart Failure Trial (A-HeFT): rationale, design, and methodologyJoseph A Franciosa, Anne L Taylor, Jay N Cohn, et al.
Circulation|March 12, 2003
Changes in brain natriuretic peptide and norepinephrine over time and mortality and morbidity in the Valsartan Heart Failure Trial (Val-HeFT)Inder S Anand, Lloyd D Fisher, Yann-Tong Chiang, et al.
American Heart Journal|May 3, 2005
Valsartan reduces the incidence of atrial fibrillation in patients with heart failure: results from the Valsartan Heart Failure Trial (Val-HeFT)Aldo P Maggioni, Roberto Latini, Peter E Carson, et al.
Circulation|December 6, 2011
Serial measurement of cardiac troponin T using a highly sensitive assay in patients with chronic heart failure: data from 2 large randomized clinical trialsSerge Masson, Inder Anand, Chiara Favero, et al.
The New England Journal of Medicine|November 10, 2004
Combination of isosorbide dinitrate and hydralazine in blacks with heart failureAnne L Taylor, Susan Ziesche, Clyde Yancy, et al.
Journal of Cardiac Failure|December 1, 2009
Relationship of quality of life scores with baseline characteristics and outcomes in the African-American heart failure trialPeter Carson, S William Tam, Jalal K Ghali, et al.
Pageof 18

Showing results (131-140 of 171) with videos related to

Sort By:
Pageof 18
Journal of Cardiac Failure|August 4, 2012
Effect of fixed-dose combined isosorbide dinitrate/hydralazine in elderly patients in the African-American heart failure trialAnne L Taylor, Michael L Sabolinski, S William Tam, et al.
Clinical Chemistry|June 17, 2006
Direct comparison of B-type natriuretic peptide (BNP) and amino-terminal proBNP in a large population of patients with chronic and symptomatic heart failure: the Valsartan Heart Failure (Val-HeFT) dataSerge Masson, Roberto Latini, Inder S Anand, et al.
JACC. Heart Failure|October 13, 2014
G-protein beta-3 subunit genotype predicts enhanced benefit of fixed-dose isosorbide dinitrate and hydralazine: results of A-HeFTDennis M McNamara, Anne L Taylor, S William Tam, et al.
Journal of Cardiac Failure|December 11, 2007
Clinical, neurohormonal, and inflammatory markers and overall prognostic role of chronic obstructive pulmonary disease in patients with heart failure: data from the Val-HeFT heart failure trialLidia Staszewsky, Maylene Wong, Serge Masson, et al.
Journal of Cardiac Failure|July 26, 2002
African-American Heart Failure Trial (A-HeFT): rationale, design, and methodologyJoseph A Franciosa, Anne L Taylor, Jay N Cohn, et al.
Circulation|March 12, 2003
Changes in brain natriuretic peptide and norepinephrine over time and mortality and morbidity in the Valsartan Heart Failure Trial (Val-HeFT)Inder S Anand, Lloyd D Fisher, Yann-Tong Chiang, et al.
American Heart Journal|May 3, 2005
Valsartan reduces the incidence of atrial fibrillation in patients with heart failure: results from the Valsartan Heart Failure Trial (Val-HeFT)Aldo P Maggioni, Roberto Latini, Peter E Carson, et al.
Circulation|December 6, 2011
Serial measurement of cardiac troponin T using a highly sensitive assay in patients with chronic heart failure: data from 2 large randomized clinical trialsSerge Masson, Inder Anand, Chiara Favero, et al.
The New England Journal of Medicine|November 10, 2004
Combination of isosorbide dinitrate and hydralazine in blacks with heart failureAnne L Taylor, Susan Ziesche, Clyde Yancy, et al.
Journal of Cardiac Failure|December 1, 2009
Relationship of quality of life scores with baseline characteristics and outcomes in the African-American heart failure trialPeter Carson, S William Tam, Jalal K Ghali, et al.
Pageof 18